0001437749-24-003016.txt : 20240202 0001437749-24-003016.hdr.sgml : 20240202 20240202190736 ACCESSION NUMBER: 0001437749-24-003016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schoenberg Mark CENTRAL INDEX KEY: 0001763581 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 24593458 MAIL ADDRESS: STREET 1: C/O UROGEN PHARMA LTD. STREET 2: 9 HA TA ASIYA STREET CITY: RA ANANA STATE: L3 ZIP: 4365007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 4 1 rdgdoc.xml FORM 4 X0508 4 2024-01-31 0001668243 UroGen Pharma Ltd. URGN 0001763581 Schoenberg Mark 400 ALEXANDER PARK DRIVE PRINCETON NJ 08540 1 Chief Medical Officer 0 Ordinary Shares 2024-01-31 4 M 0 2000 A 150560 D Ordinary Shares 2024-01-31 4 S 0 1137 15.74 D 149423 D Ordinary Shares 2024-01-31 4 M 0 1333 A 150756 D Ordinary Shares 2024-01-31 4 S 0 758 15.74 D 149998 D Ordinary Shares 2024-01-31 4 M 0 3333 A 153331 D Ordinary Shares 2024-01-31 4 S 0 1894 15.74 D 151437 D Restricted Stock Units 2024-01-31 4 M 0 2000 0 D Ordinary Shares 2000 0 D Restricted Stock Units 2024-01-31 4 M 0 1333 0 D Ordinary Shares 1333 1334 D Restricted Stock Units 2024-01-31 4 M 0 3333 0 D Ordinary Shares 3333 6667 D Restricted Stock Units 2024-01-31 4 A 0 10000 0 A Ordinary Shares 10000 10000 D Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. /s/ Jason D. Smith, Attorney-in-Fact 2024-02-02